<DOC>
	<DOCNO>NCT01830400</DOCNO>
	<brief_summary>This Non-interventional Prospective Study . Centres enrol adult patient partial-onset seizure without secondary generalisation clinician decide initiate Eslicarbazepine Acetate ( ESL ) adjunctive therapy prior decision take part study . Patients enrol study sufficiently control one drug license use monotherapy partial-onset seizure . Patients see baseline normal clinical visit interval . Patients study assessed efficacy tolerability baseline least 3 6 month baseline .</brief_summary>
	<brief_title>A Post-marketing Study Evaluating Eslicarbazepine Acetate ( ESL ) Adjunctive Treatment Partial-Onset Seizures ( Study E2093-E044-404 ) ( EPOS )</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>The decision prescribe ESL make physician independently his/her decision include patient study Patients treat one drug license monotherapy partial onset seizure Based physician 's clinical judgment , patient seizure activity control sufficiently current monotherapy patient 's best interest prescribe adjunctive ESL Patient prescribe ESL longer 2 week baseline Treatment ESL commence line drug 's license Eslicarbazepine Acetate ( ESL ) Summary Product Characteristics ( SPC ) Aged 18 year old Signed write informed consent Patients start ESL outside approve SPC enrolment Simultaneous participation interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ESL</keyword>
	<keyword>Partial onset seizure</keyword>
	<keyword>Retention Rate</keyword>
	<keyword>Seizure Control</keyword>
	<keyword>Antiepileptic</keyword>
	<keyword>Secondary Generalisation</keyword>
</DOC>